“I am pleased with Cytek’s strong revenue growth and continued execution throughout 2022,” said Dr. Wenbin Jiang, CEO of Cytek Biosciences. “In addition to reporting strong financial results, we ...

Total revenue was $58.6 million, or $58.2 million on a non-GAAP constant currency basis, for the fourth quarter of 2023, representing 21% and 14% increases, respectively, over the corresponding period ...

First quarter revenue grew 44% compared to prior yearFREMONT, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial ...

Total revenue was $200.5 million, or $201.3 million on a non-GAAP constant currency basis, for the full year 2024, representing 3.9% and 3.9% increases, respectively, over the full year 2023 Expanded ...

“I am encouraged by the resilience of our portfolio amidst a challenging macroeconomic backdrop, exemplified by double-digit revenue growth in Cytek cell sorters and our service business, and strength ...

"Our team ended the year on a strong note, executing well across our business and continuing to expand our installed instrument base significantly. We are also pleased with the increased demand we are ...

“Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position,” said Wenbin Jiang, CEO of Cytek Biosciences. “As we ...